Lorundrostat Phase 3 data in uncontrolled blood pressure, CKD going to ESH 2026
Mineralys Therapeutics (Nasdaq: MLYS) announced it will present new Phase 3 data from its Launch-HTN trial for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). The data, focusing on patients with uncontrolled hypertension and chronic kidney disease (CKD), will be presented orally on May 30, 2026, by Liffert Vogt, MD, PhD. The trial evaluated lorundrostat's efficacy and safety in adults whose blood pressure remained uncontrolled despite existing antihypertensive medications, with the primary endpoint being the change from baseline in systolic BP at six weeks.
MAY 12·Stock Titan→
[144] Mineralys Therapeutics, Inc. SEC Filing
Mineralys Therapeutics, Inc. filed a Form 144 notice for the proposed sale of 2,171 shares of common stock through a broker-assisted cashless exercise, effective May 11, 2026. The filing also documents multiple prior open-market dispositions by David Rodman between February and April 2026, including significant share blocks. Analysts consider the filing neutral, indicating routine liquidity events and required regulatory notice without immediate broader market impact unless volume is high relative to outstanding float.
MAY 5·MyChesCo→
Mineralys to Report First-Quarter Results on May 6
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will announce its first-quarter financial results on Wednesday, May 6, after market close. The company will also hold a conference call at 4:30 p.m. Eastern Time to discuss the results, with details provided for both domestic and international participants, as well as a live webcast link. Mineralys focuses on developing therapies for hypertension and related conditions, with lorundrostat as its lead product candidate.
